Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

The latest confirmation likely reflects follow-up testing of a San Francisco child whose exposure to the virus is still under ...

The trial, conducted in the United Kingdom, found that a procalcitonin-guided algorithm didn't reduce IV antibiotic duration ...

Australia imports about 90 per cent of its medicine, and this makes us incredibly vulnerable to any supply disruption. But it ...

Study findings indicated a transition from IV to enteral triazole therapy as a feasible option for pediatric patients with invasive candidiasis.

BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...